may
reuter
health
us
food
drug
administr
fda
said
clear
biorad
laboratori
blood
test
aspergillu
caus
invas
fungal
infect
fatal
immunocompromis
patient
product
first
rapid
lab
test
infect
agenc
said
tradit
test
method
take
week
note
fungal
infect
often
occur
leukemia
patient
organ
bone
marrow
transplant
patient
patient
whose
immun
system
compromis
ill
chemotherapi
although
affect
thousand
peopl
year
accord
feder
figur
mortal
rate
rang
fda
said
clearanc
base
comparison
test
done
cancer
center
blood
sampl
peopl
result
show
new
test
sensit
specif
fda
earlier
clear
biorad
test
use
trial
fund
nation
institut
health
aim
find
potenti
new
treatment
infect
may
reuter
health
marilynn
larkin
superspread
sever
acut
respiratori
syndrom
sar
unlik
infect
particularli
virul
form
diseas
best
dealt
isol
quarantin
word
panelist
confer
sar
context
emerg
infecti
threat
held
new
york
academi
scienc
saw
clearli
singapor
secondari
case
link
case
quarantin
limit
transmiss
assert
dr
larri
anderson
us
center
diseas
control
prevent
atlanta
peopl
infect
other
nt
infect
becom
superspread
toronto
experi
similar
said
dr
donald
low
mt
sinai
treat
earli
case
case
b
patient
infect
other
congest
heart
failur
patient
infect
sar
recogn
earli
enough
patient
went
home
infect
famili
member
healthcar
worker
emerg
depart
coronari
surgeri
ward
one
instanc
health
care
worker
becam
infect
intub
consid
highrisk
activ
sar
patient
infect
probabl
due
droplet
dispers
occur
intub
becam
difficult
said
may
reuter
health
marilynn
larkin
spirit
fullday
symposium
new
york
academi
scienc
scientist
industri
us
nation
institut
allergi
infecti
diseas
niaid
agre
unpreced
rapid
progress
made
identifi
potenti
vaccin
strategi
drug
treatment
sever
acut
respiratori
syndrom
sar
peopl
galvan
particularli
china
massiv
effort
underway
develop
kill
subunit
vaccin
viral
vector
test
use
convalesc
serum
diseas
said
symposium
chair
dr
scott
hammer
chief
divis
infecti
medicin
columbia
presbyterian
medic
center
new
york
citi
dr
david
ho
scientif
director
aaron
diamond
aid
research
center
also
new
york
citi
report
took
candid
fusion
peptid
could
inhibit
sar
viru
entri
replic
hong
kong
week
ago
preliminari
result
suggest
antivir
activ
vari
concentr
none
toxic
appear
peptid
block
sar
fusion
block
hiv
fusion
dr
c
richter
king
genvec
gaithersburg
maryland
said
compani
one
sever
use
adenoviru
vector
technolog
target
surfac
glycoprotein
sar
use
similar
technolog
hiv
malaria
dengu
viru
note
versatil
well
toler
larg
scale
dr
thoma
monath
acambi
cambridg
massachusett
said
compani
collabor
close
veterinarian
work
coronaviru
vaccin
treat
anim
even
though
unclear
whether
coronaviru
caus
sar
jump
speci
barrier
evolv
separ
repres
merck
bristol
myer
squibb
pfizer
particip
short
panel
discuss
acknowledg
work
underway
vaccin
treatment
offer
specif
caution
best
commerci
avail
vaccin
might
expect
year
editor
comment
although
vaccin
sar
probabl
year
away
interest
keep
inform
mani
effort
progress
develop
one
may
reuter
health
maggi
fox
immun
smallpox
last
virtual
lifetim
research
said
report
suggest
anyon
vaccin
past
still
protect
viru
use
bioterror
attack
test
peopl
vaccin
long
year
ago
show
everyon
least
immun
deadli
viru
team
oregon
health
scienc
univers
ohsu
found
find
may
offer
comfort
older
assum
immun
long
gone
unit
state
stop
routin
vaccin
smallpox
world
health
organ
announc
diseas
erad
nineti
percent
american
older
vaccin
smallpox
least
mean
mani
million
peopl
least
immun
viru
said
ohsu
microbiologist
immunologist
mark
slifka
design
smallpox
plan
offici
assum
one
much
immun
year
slifka
erika
hammarlund
other
ohsu
among
team
test
premis
look
blood
peopl
vaccin
past
everyon
ever
vaccin
smallpox
degre
immun
slifka
told
meet
american
societi
microbiolog
peopl
came
differ
state
countri
nt
differ
whether
vaccin
oregon
florida
franc
hammarlund
told
news
confer
specif
recruit
peopl
time
slifka
said
littl
effect
burst
immun
right
get
vaccin
person
overal
immun
seem
return
set
point
even
multipl
immun
peopl
immun
still
becom
ill
even
less
like
die
smallpox
pass
diseas
other
hammarlund
said
least
half
test
high
level
antibodi
past
studi
done
smallpox
still
around
protect
seriou
infect
editor
comment
data
support
old
observ
protect
death
due
smallpox
last
mani
year
vaccin
howev
import
note
although
protect
death
protect
develop
smallpox
diminish
time
infect
individu
capabl
infect
other
spread
diseas
outbreak
may
reuter
health
martha
kerr
advent
highli
activ
antiretrovir
therapi
haart
hiv
infect
preval
diseaseassoci
diarrhea
problem
still
persist
nearli
patient
accord
studi
investig
new
york
univers
digest
diseas
week
annual
meet
american
gastroenterolog
associ
dr
uzma
siddiqui
present
center
find
studi
hivinfect
patient
control
attend
primari
care
clinic
subject
ask
bowel
statu
gener
health
qualiti
life
exclud
patient
attend
gi
clinic
reduc
bia
told
reuter
health
investig
found
hivinfect
patient
report
diarrhea
past
month
compar
control
addit
hivposit
patient
report
bowel
movement
day
within
past
month
compar
control
similar
number
group
report
bowel
movement
per
day
within
past
month
p
ask
describ
stool
hiv
patient
describ
loos
liquid
compar
control
overthecount
antidiarrh
medic
taken
hivinfect
patient
compar
control
hivassoci
diarrhea
frequent
report
advent
haart
dr
siddiqui
told
reuter
health
patient
hospit
often
manag
condit
brought
nobodi
look
look
back
patient
chart
mention
diarrhea
continu
major
problem
patient
